Archive · 16 Jun 2025
Granules India Plans R&D Expansion and Capacity Augmentation
Granules India, a drug company, is growing!
They are expanding to make more medicine and focusing on specialized treatments like ADHD and cancer drugs.
They are increasing factory capacity to make many more pills.
They bought a company in Europe to make different kinds of medicines.
The company also has many new medicine ideas being reviewed by the government.
Granules India is also looking to buy other companies to get new skills or technologies.
They are planning to be a major player in drug research and development.
Granules India plans to increase installed capacity from 2.5 billion to 25 billion units.
The company is focusing on high-margin offerings, including controlled substances and oncology molecules.
Granules India acquired Senn Chemicals AG, expanding into peptides and CDMO in Europe.
Granules India has 127 dossiers filed globally, with 85 in the US and 16 awaiting approval.
The company is evaluating inorganic opportunities for skills or technology acquisition.
- Who
- Granules India, led by Executive Director Priyanka Chigurupati.
- What
- Granules India's expansion plans, including capacity augmentation and R&D focus.
- When
- Over the next few years.
- Where
- Focusing on the US and expanding to other regions.
- Why
- To enhance product mix, increase capacity, and expand into new markets and high-margin offerings.
Potential Impact of US Tariffs
PBMs and the generic value chain
Tariffs on Pharma
Potential Impact of US Tariffs
Tariffs are likely for branded pharma.
PBMs and the generic value chain
Impact could be different for generic manufacturers depending on tariff and introspection of PBMs practices.
- Company
- Granules India
- Executive Director
- Priyanka Chigurupati
- Current Capacity
- 2.5 billion units
- Planned Capacity
- 25 billion units
- Acquisition
- Senn Chemicals AG
- Dossiers Filed
- 127 globally
- Focus Areas
- Controlled substances, oncology molecules, peptides
